Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.
Separately, Weiss Ratings upgraded Chemomab Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce”.
Get Our Latest Research Report on CMMB
Chemomab Therapeutics Stock Performance
Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) last announced its quarterly earnings data on Thursday, August 20th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.12).
Institutional Investors Weigh In On Chemomab Therapeutics
An institutional investor recently raised its stake in Chemomab Therapeutics stock. Kestra Private Wealth Services LLC lifted its holdings in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB – Free Report) by 19.3% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 61,710 shares of the company’s stock after purchasing an additional 10,000 shares during the period. Kestra Private Wealth Services LLC owned 0.86% of Chemomab Therapeutics worth $97,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 46.05% of the company’s stock.
Chemomab Therapeutics Company Profile
Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory and fibrotic diseases. The company’s research is based on the role of CCL24, a chemokine believed to contribute to inflammation, tissue remodeling and fibrosis across multiple organs.
Chemomab’s lead product candidate is CM-101, an investigational monoclonal antibody designed to block CCL24 activity. The company is evaluating CM-101 in diseases including systemic sclerosis, also known as scleroderma, and primary sclerosing cholangitis, a chronic liver disease.
Further Reading
- Five stocks we like better than Chemomab Therapeutics
- Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?
- The AI Buildout Needs Power It Cannot Get: 4 Energy Stocks Already Have It
- McDonald’s Is Undergoing a Massive New Growth Strategy. Can It Win Back Consumers?
- MGM Resorts Stock Sinks After Diller Deal Collapse: Overreaction or Warning?
Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
